We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Flow Cytometer Cleared for Diagnostic Use

By LabMedica International staff writers
Posted on 04 Nov 2013
The US Food and Drug Administration (FDA) has cleared a flow cytometry system for in vitro diagnostic use by immunophenotyping. More...
With superior detection capabilities, it provides accurate measurements, including for rare events critical to clinical diagnosis and monitoring.

The “Navios” flow cytometry system from Beckman Coulter Life Sciences (Brea, CA, USA) has received 510(k) clearance from the US FDA for in vitro diagnostic use. It has also received an Import Medical Device Registration Certificate from the China FDA. This clinical system provides analytical excellence by coupling extraordinary sensitivity, resolution, and dynamic range with high-speed data collection.

Ready to use, preoptimized CYTO-STAT tetraCHROME reagents make sample preparation easy. A no-wash protocol reduces sample handling and increases laboratory safety. The Navios Tetra system, for simultaneous identification and enumeration of T, B, and NK lymphocytes in whole blood, provides an easy-to-use solution for multicolor flow cytometric analysis of lymphocyte subsets as well as CD4+ and CD8+ T cell subsets ratios.

Navios software reports cellular characteristics such as size, granularity, and phenotype, and combines data in one automated, customized report with plots and formulas. A variety of reporting options are available. Easy integration with a variety of automated preparation devices and LIS-readiness offers secure, high-throughput results, even at high volumes.

Navios is optimized for signal to noise resolution and its quick and easy setup of automated walk-away processing improves workflow while its remote diagnostics reduces downtime and increases lab productivity. Patented electronics provide accurate and efficient digital signal processing at high event rates over a wide dynamic range of fluorescence intensities. These benefits are packaged in a compact analyzer that delivers stable performance over long periods of time and across a wide range of operating temperatures.

In the USA, the Navios flow cytometer is currently cleared for clinical immunophenotyping in conjunction with proprietary Navios Tetra software and CYTO-STAT tetraCHROME reagents. In the USA, all other uses are currently for research only. The Navios has additional capabilities to meet expanded (e.g., research) needs. It incorporates 12 detectors—10 fluorescence detectors and 2 light scattering detectors. Simultaneous measurements of integral, peak, and width are available for all scatter measurements and up to 10 fluorescent parameters.

According to Mario Koksch, vice president of Beckman Coulter Life Sciences’ Flow Cytometry Business Unit, “Every aspect of the optics design of Navios increases application performance, sensitivity, and resolution. These systems enhance flow laboratory efficiency by increasing productivity and improving the reliability and reproducibility of results, thus reducing the cost of flow cytometry testing.”

Related Links:

Beckman Coulter Life Sciences



Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Rapid Flu Test
Influenza A&B Rapid Test Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.